Skip to main content

Usana Health Sciences Value Stock - Dividend - Research Selection

Usana health sciences

ISIN: US90328M1071 , WKN: 923145

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

General

 

USANA Health Sciences, Inc., a Utah corporation, was founded in 1992 by Myron W. Wentz, Ph.D. We develop and manufacture high-quality, science-based nutritional and personal care products with a primary focus on promoting long-term health and reducing the risk of chronic degenerative disease. In so doing, we are committed to continuous product innovation and sound scientific research. We have operations in 19 markets worldwide, where we distribute and sell our products by way of direct selling. We have chosen this distribution method as we believe it is the most conducive to meeting our vision as a company, which is improving the overall health and nutrition of individuals and families around the world. Our net sales in fiscal year 2014 were $790.5 million, of which 81.8% were in markets outside of the United States. As a U.S.-based multi-national company with an expanding international presence, our operating results are sensitive to currency fluctuations, as well as economic and political conditions in markets throughout the world. Additionally, we are subject to the various laws and regulations in the United States, China, and the other markets in which we operate with respect to the products that we sell and to our method of distribution.

 

Our customer base comprises two types of customers: "Associates" and "Preferred Customers." Associates share in our company vision by acting as independent distributors of our products in addition to purchasing our products for their personal use. Preferred Customers purchase our products strictly for personal use and are not permitted to resell or to distribute the products. As of January 3, 2015, we had 349,000 active Associates and 81,000 active Preferred Customers worldwide.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


USANA Executive Chairman Kevin Guest Calls for a "Great Re-Engagement" Rooted in Trust, Empathy, Purpose

2025-11-03
As business leaders worldwide focus on re-energizing workforces after years of upheaval, Kevin Guest, Executive Chairman of USANA Health Sciences (NYSE: USNA), is urging CEOs to lead with renewed authenticity, empathy, and moral clarity—principles he calls "the real foundation of sustainable success."

The Top 5 Analyst Questions From USANA’s Q3 Earnings Call

2025-10-29
USANA's third quarter results were met with a negative market reaction, as investors responded to a significant reduction in full-year guidance and ongoing operational pressures. Management attributed the quarter’s performance to the global launch of an enhanced compensation plan and noted initial softness in sales and Brand Partner productivity as the field adapted to these changes. CEO Jim Brown described the transition period as challenging, stating, “We didn’t have the best quarter or it did

USANA Health Sciences (USNA) Price Target Decreased by 36.07% to 39.78

2025-10-29

USANA Health Sciences, Inc. 2025 Q3 - Results - Earnings Call Presentation

2025-10-28
2025-10-28. The following slide deck was published by USANA Health Sciences, Inc.

The S&P 500 Just Added 2 Stocks—and Booting 2 Other Stocks.

2025-10-28
Honeywell and DuPont are hiving off companies in the coming days, and both are going into the S&P 500.

Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

2025-10-27
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:

USANA Health Sciences (USNA): Margin Decline Challenges Bullish Turnaround Narratives

2025-10-24
USANA Health Sciences (USNA) reported a mixed set of results in its latest earnings release, with revenue growth forecast at just 0.1% per year. This lags behind the broader US market's expected 10% annual increase. Current net profit margins have narrowed sharply to 1.9%, down from 6.3% the prior year. Over the past five years, the company’s earnings have shrunk by 28.6% per year, including negative earnings growth in the most recent period. Despite these declines, the outlook appears to...

Stocks making big moves this week: Integer Holdings, Duolingo, Pegasystems, USANA, and Monolithic Power Systems

2025-10-24
Check out the companies making headlines this week:

Usana Health Sciences Inc (USNA) Q3 2025 Earnings Call Highlights: Strategic Moves and Sales ...

2025-10-23
Usana Health Sciences Inc (USNA) reports significant sales growth in its venture companies and outlines strategic cost reduction initiatives to enhance operational efficiency.

USNA Q3 Deep Dive: Compensation Plan Changes and Cost Cuts Drive Strategic Pivot

2025-10-23
Health and wellness products company USANA Health Sciences (NYSE:USNA) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.7% year on year to $213.7 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $920 million at the midpoint. Its non-GAAP loss of $0.15 per share was in line with analysts’ consensus estimates.